The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

The present invention relates to compositions and methods for treating cancers in a subject in need thereof. The invention more particularly relates to methods of treating cancers by inhibiting PLA2-GIB in a subject in need thereof.

The present invention is directed to improved methods of preparing cells and compositions for therapeutic uses.

This disclosure pertains to compositions and methods for reducing serum cholesterol in mammalian subjects. The exemplary compositions comprise mixtures of HSP27 protein or fragments thereof, a HSP25 protein or fraction thereof, a recombinant rHSP25 peptide, or a recombinant HSP27 peptide in a mixture with an adjuvant. The compositions may optionally comprise anti-HSP27 antibody. The methods for reducing serum cholesterol in mammalian subjects relate to the use of the compositions to increase the subjects' levels of serum HSP27 and/or anti-HSP27 antibodies.

The invention provides compositions and methods for inhibiting tumor growth by up-regulating and/or supplementing SOCS3 in tumor and/or tumor-associated tissues of a subject or in cells in vitro. Compounds capable of up-regulating SOCS3, including flavanones, or otherwise of up-regulating the ACh pathway, e.g., at the NMJ, are identified and provided, as are methods for identifying additional agents as inducers of SOCS3.

The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.

The present invention is directed to a peptide, multimer, conjugate, analog, derivative or mimetic thereof that inhibits the activity of VISTA. The invention further contemplates therapeutic use of the VISTA antagonist peptide, multimer, conjugate, derivative or mimetic thereof, including treating or preventing cancer, bacterial infections, viral infections, parasitic infections and fungal infections, as well as research uses of the antagonist.

The invention encompasses methods of treatment of interferon gamma (IFN-γ)-mediated diseases using IFN-γ inhibitors, such as anti-huIFN-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-γ antibody.

A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least of the polypeptide fragments is antigenic.

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.